Pneumothorax is the most common device related serious adverse event that is associated with the spiration valve system.In the improve study, the incidence of serious pneumothorax was 14.2%, with over 75% of the serious pneumothorax events occurring within the first 3 days post-procedure.Early-onset pneumothorax in the treatment group likely resulted from lung conformation changes due to acute reduction in lung volume by valve therapy, triggering rapid expansion of the ipsilateral non-targeted lobe leading to a pneumothorax.(criner et al.Improving lung function in severe heterogenous emphysema with the spiration® valve system (emprove): a multicenter, open-label, randomized, controlled trial.Am j respir crit care med.2019 jul 31.Doi: 10.1164/rccm.201902-0383oc.[epub ahead of print]).However, it should be noted that pneumothorax events are also recognized as an indicator of successful target lobe occlusion and when managed according to published expert guidelines (valipour et al.Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema ¿ potential mechanisms, treatment algorithm and case examples.Respiration 2014; 8: 513-521), subjects with pneumothorax events experienced clinical benefits similar to that in subjects without pneumothorax events (criner et al.Ajrccm 2019 jul 31.Doi: 10.1164/rccm.201902-0383oc.[epub ahead of print].The reported event aligns with the experience in the emprove clinical trial and is an expected adverse event associated with the spiration valve system.
|